Gabrielle Cosel

Manager, Drug Safety , The Pew Charitable Trusts
Headshot Cosel 435 Full

To reach this expert, please contact:

Amy E. Allen 
Administrative Assistant

As manager of Pew's drug safety project, Cosel works on federal initiatives to ensure the safety and oversight of the U.S. pharmaceutical supply chain. Prior to joining Pew, Cosel worked on issues of pharmaceutical safety and appropriate prescribing for national advocacy Organization Community Catalyst, and in grassroots development and capacity-building with the Fund for Public Interest Research in Cambridge, Massachusetts.

Cosel received her M.Sc. in human rights from the London School of Economics and a BA from Yale University.


Subscribe to This Feed

Expert Profile: Gabrielle Cosel


Gabrielle Cosel, Project Manager, Drug Supply Safety


''FDA calls for more congressional oversight on global drug economy''

Media Coverage

"The Food and Drug Administration called on Congress Tuesday to make the laws that govern the global prescription drug economy stronger. In a report released Tuesday by the Pew Health Group, researchers looked at the globalization of pharmaceutical production and the domestic distribution of prescription drug, with an eye on how the FDA can more effectively regulate both."



Case Studies: How Unsafe Drugs Can Reach Patients

Issue Brief

The following case studies illustrate breaches to the pharmaceutical supply chain—the route a drug travels from its raw material origins to the delivery of a finished medicine. These examples, all of which are discussed in Pew Health Group’s report After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, demonstrate the different ways in which contaminated, fake, or otherwise unsafe medicine can reach patients, and underscore the need for reform.


Heparin: A Wake-Up Call on Risks to the U.S. Drug Supply

Issue Brief

While the vast majority of drugs in American pharmacies and medicine cabinets are safe, globalization and reliance on outsourced manufacturing creates new risks, including deliberate tampering with ingredients and inadequate quality controls in plants that operate largely outside the scrutiny of the FDA.


After Heparin


This report provides an overview of the complex pharmaceutical supply chain from manufacturing through distribution of the finished drug, and advances proposed policy solutions to help reduce the risks of counterfeit, adulterated and substandard drugs.

Read two fact sheets describing the heparin adulteration and other examples of breaches to the U.S. drug supply.

View an interactive graphic presenting an overview of today's globalized pharmaceutical supply chain and its vulnerabilities.